Novo Nordisk A/S: DegludecPlus provides superior glycaemic control compared to insulin glargine in a phase 3a trial in Japanese people with type 2 diabetes

Novo Nordisk today announced clinical results from a 26-week phase 3a treat-to-target study comparing DegludecPlus, a soluble combination of ultra-long-acting insulin degludec and insulin aspart, to insulin glargine in Japanese people with type 2 diabetes inadequately controlled on oral antidiabetic drugs. This is the 18th announced phase 3a study in the Degludec and DegludecPlus clinical trial development programme. Further information Media: Investors: Katrine Sperling Klaus Bülow Davidsen Tel: (+45) 4442 6718 Tel: (+45) 4442 3176 [email protected] [email protected] Frank Daniel Mersebach Tel: (+45) 4442 0604 [email protected] Lars Borup Jacobsen Tel: (+45) 3075 3479 [email protected] In North America: Ambre Morley Jannick Lindegaard Tel: (+1) 609 216 5240 Tel: (+1) 609 786 4575 [email protected] [email protected] Company Announcement no 70 / 2011

The release as fetched from its publisher. novonordisk.com ↗